Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Jul 4;264(1):63-7.

Kidney transplantation under FK 506

T E Starzl  1 , J Fung, M Jordan, R Shapiro, A Tzakis, J McCauley, J Johnston, Y Iwaki, A Jain, M Alessiani, et al.
Affiliations

Kidney transplantation under FK 506

T E Starzl et al. JAMA. .

Abstract

The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13 months, all but 2 of the 36 patients are alive, 29 (81%) are dialysis free, and most have good renal function. Twenty of the 29 dialysis-free patients are receiving no or low-dose (2.5 to 5.0 mg/d) prednisone therapy. Only one kidney was lost to cellular rejection. However, patients who had antidonor cytotoxic antibodies in current or historical serum samples had a high rate (3 of 9) of irreversible humoral rejection. A low incidence of posttransplant hypertension was noteworthy. Hirsutism and gingival hyperplasia were not observed. Serum cholesterol levels in patients who took FK 506 were unexpectedly low, and the effect on the level of uric acid was minimal. The side effects of FK 506 therapy include nephrotoxicity, neurotoxicity, and potential induction of a diabetic state. These are similar to the side effects of cyclosporine use, but probably less severe. The seeming safety, efficacy, and relative freedom from side effects of FK 506 encourage further trials in kidney transplantation.

PubMed Disclaimer

References

    1. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain A. FK-506 for human liver, kidney and pancreas transplantation. Lancet. 1989;2:1000–1004. - PMC - PubMed
    1. Todo S, Fung JJ, Demetris AJ, Jain A, Venkataramanan R, Starzl TE. Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc. 1990;22:13–16. - PMC - PubMed
    1. Fung JJ, Todo S, Jain A, et al. Conversion of liver allograft recipients with cyclosporine related complications from cyclosporine to FK 506. Transplant Proc. 1990;22:6–12. - PMC - PubMed
    1. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from streptomyces, I: fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot. 1987;40:1249–1255. - PubMed
    1. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a streptomyces, II: immunosuppressive effect of FK-506 in vitro. J Antibiot. 1987;40:1256–1265. - PubMed

Publication types